News

AFT Pharma reports growth and global expansion

FINANCIAL RESULTS FOR THE SIX MONTHS TO 30 SEPTEMBER 2023

AFT welcomes US FDA approval for sale of Maxigesic IV^®

AFT Pharmaceuticals announces the US FDA has approved Maxigesic IV®, the intravenous form of its patented pain relief medicine, for sale in the US, which represents AFT’s second FDA approval within one year.

AFT Pharmaceuticals to announce half year interim results

AFT Pharmaceuticals announced today that it intends to release on Thursday November 23 2023 its half year interim results for the period ended September 30 2023.

AFT appoints Andrew Lane as independent director

AFT Pharmaceuticals today announces the appointment of Andrew Lane as an independent non-executive director.

Retirement of Jon Lamb

Independent director Jon Lamb today retired from the board following his announcement at the ASM.

AFT Orphan Pharmaceuticals judgment

AFT Pharmaceuticals advises of the release yesterday evening by the High Court at Auckland of its judgment upholding in part claims by PBL Solutions Limited (PBL) against AFT, and dismissing others.

Filter

19/04/2023

AFT submits Maxigesic IV® packaging data to the US FDA

AFT Pharmaceuticals announces it has submitted to the US Food and Drug Administration (FDA) data the regulator requested, as it considers registration of the company’s patented intravenous pain relief medicine Maxigesic IV.

11/04/2023

AFT gains first product registration in China for Crystawash Extend and extends Maxigesic IV licensing

As a result of these launches and recent sales AFT will enter the new financial year with Maxigesic sold in 61 countries in various dose forms, 15 more than where we were in March 2022.

14/03/2023

Maxigesic Rapid® tablets gain US FDA approval

AFT Pharmaceuticals (NZX.AFT, ASX.AFP) today announces the US Food and Drug Administration has approved a rapid release tablet form of Maxigesic for the management of mild to moderate acute pain in the US.

Financial Results For Half Year Ended 30 September 2020

02/02/2023

AFT to develop antibiotic eye drop

AFT Pharmaceuticals to develop antibiotic eye drop

09/01/2023

2023 New Year letter to investors

AFT Pharmaceuticals releases New Year letter to shareholders.

24/11/2022

AFT extends growth investment as sales surge

AFT PHARMACEUTICALS LTD FINANCIAL RESULTS FOR THE SIX MONTHS TO 30 SEPTEMBER 2022

11/10/2022

AFT Pharmaceuticals to announce half year interim results on Thursday November 24 2022

AFT Pharmaceuticals announces the analysis of its study examining its medicine Pascomer as a topical treatment for facial angiofibromas (FA) associated with Tuberous Sclerosis Complex (TSC).

Pascomer Trial Results Timber Termination

28/07/2022

AFT Completes Pascomer Clinical Study and Takes Back Rights in North America

AFT Pharmaceuticals announces the analysis of its study examining its medicine Pascomer as a topical treatment for facial angiofibromas (FA) associated with Tuberous Sclerosis Complex (TSC).

22/07/2022

Dr Doug Wilson to step down from AFT Board

AFT Pharmaceuticals today announces that Dr Doug Wilson will step down from its Board of Directors

07/07/2022

AFT and RooLife launch OTC medicines online in China

AFT Pharmaceuticals and RooLife Group today announce they have launched a range of AFT’s over the counter (OTC) pharmaceuticals through their store on the China Cross Border E-Commerce (CBEC) online platform Tmall Global.

07/04/2022

AFT Sponsors APP Conference 2022 with Crystawash Extend

AFT Pharmaceuticals participate in the Australian Pharmacy Professional (APP) Conference and Trade Exhibition in May 2021.

24/02/2022

AFT Pharmaceuticals partners with Farmaforce

Farmaforce, an award-winning contract sales organisation offering innovative solutions to the Australian pharmaceutical industry, today confirmed its formal partnership with AFT Pharmaceuticals (AFT) to provide “best in class” representation to healthcare practitioners and professionals.